Recent Quotes (30 days)

You have no recent quotes
chg | %

Kane Biotech Inc  

(Public, CVE:KNE)   Watch this stock  
Find more results for KNE
0.0450
+0.0050 (12.50%)
Delayed:   10:16AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.05 - 0.05
52 week 0.03 - 0.09
Open 0.05
Vol / Avg. 50,000.00/208,918.00
Mkt cap 4.84M
P/E     -
Div/yield     -
EPS -0.02
Shares 107.53M
Beta 0.39
Inst. own     -

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1495.64% -3854.20%
Operating margin -1422.90% -3634.80%
EBITD margin - -3541.15%
Return on average assets -108.50% -83.39%
Return on average equity -171.64% -123.84%
CDP Score - -

Address

Suite 162, 196 Innovation Drive
WINNIPEG, MB R3T 2N2
Canada
+1-204-4531301 (Phone)
+1-204-4747552 (Fax)

Website links

Description

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of products that prevent and remove microbial biofilms. It is involved in research and development of animal and human health products. The Company's technologies include DispersinB, AloSera, Aledex, Strix NB, bluestem and KBI Disinfectant. The Company is focused on the companion animal market with Strix NB brand for the veterinary segment and bluestem brand for the pet over the counter (OTC) retail market. The Company's products include The Company has a number of formulations in development, including formulations with antibiotics and the antibiofilm enzyme beta-N-Acetylglucosaminidase and antibiofilm-antimicrobial (antibiotic free) formulations for both the veterinary and human markets.

Officers and directors

Philip Renaud Independent Chairman of the Board
Mark William Ahrens-Townsend President, Chief Executive Officer
Mark Matthewson Chief Financial Officer
Arvind K. Joshi M.D. Independent Director
Mark H. Nawacki Independent Director
Sarah Prichard Independent Director